Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

It is most effective at managing blood sugar overnight and between meals. While long-acting insulin is slow to reach the bloodstream and has a relatively low peak, it stabilizes the “plateau ...

Merilog marks the third insulin biosimilar to receive FDA approval, following the greenlight of two long-acting biosimilar insulin products in 2021. Diabetes, a chronic disease impacting more than ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The rapid-acting insulin aspart biosimilar joins two prior long-acting insulin biosimilar products approved in 2021. Biosimilars are highly similar to already approved products and have no ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...

The FDA noted that Merilog is the third insulin biosimilar product to get its approval. In 2021, the agency had approved two long-acting insulin biosimilar products. A biosimilar is a biological ...

Merilog also marks the third insulin biosimilar approved in the United States, following two long-acting biosimilars approved in 2021. 1 "The FDA has now approved three biosimilar insulin products to ...